Biotoscana Investments SA (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced its financial results for 2018 on Friday.
The company reported an increase in net revenue for 2018 of 10% in constant currency, positively impacted by its Dosa drug, marking BRL821m.
The firm posted net income at BRL63m in 2018 compared with BRL17m in 2017.
Gross profit increased by 12% vs 2017, in constant currency.
Gross margin of 51% (including hyperinflation adjustments) vs 54% in 2017.
OPEX are in line with 34% of net revenues in 2018.
(1USD=4BRL)
Acerus and Aytu Bioscience to Co-promote Natesto in the United States
Amgen reports financial results for Q2 2019
Pfizer to integrate Upjohn with Mylan to establish new global pharmaceutical company
Neurocrine Biosciences reports half-year ended 30 June 2019 financial results
Thermo Fisher Scientific reports financial results for Q2 2019
Veloxis Pharmaceuticals revises 2019 outlook
NANOBIOTIX collects revenues of EUR31.9,000 for Q2 2019
Seattle Genetics incurs net loss of USD79.2m in Q2 2019
Baxter's board announces USD0.22 per share dividend pay order
Johnson & Johnson declares dividend of USD0.95 per share for Q3 2019
Sun Pharma Launches Ezallor Sprinkle in the US for People Who Have Difficulty Swallowing
PanTheryx Aims to End Diarrheal Disease in Cambodia
CCA Industries Inc swings to income of USD349,320 for Q2 2019
Oncimmune Holdings signs commercial collaboration with R-Pharm JSC